New study aims to see how triple combination therapy with sotatercept affects pulmonary vascular resistance in patient with newly diagnosed pulmonary arterial hypertension

New study aims to see how 24 weeks of triple therapy with an endothelin receptor antagonist (ERA), a phosphodiesterase-5 inhibitor (PDE5i), and sotatercept, affects pulmonary vascular resistance (PVR) in patients with newly diagnosed pulmonary arterial hypertension. SIRIUS is a 24-week, single-arm, open-label study with up to 42 days of screening and a 28-day safety follow-up. […]

New study aims to see how triple combination therapy with sotatercept affects pulmonary vascular resistance in patient with newly diagnosed pulmonary arterial hypertension Read Post »

Thirty Years of Progress in Pulmonary Arterial Hypertension Treatment: From Despair to Hope, Chinese Medical Journal, May 19, 2026

Researchers from China have traced the remarkable 30-year evolution of pulmonary arterial hypertension treatment, from a disease with no effective options to one on the cusp of a potential cure. What was once described as the “cancer of cardiovascular diseases” — with a median survival of just 2.8 years after diagnosis — has become a

Thirty Years of Progress in Pulmonary Arterial Hypertension Treatment: From Despair to Hope, Chinese Medical Journal, May 19, 2026 Read Post »

Efficacy and safety of sotatercept in patients with pulmonary arterial hypertension (PAH) associated with connective tissue disease (CTD), ATS international conference, May 18, 2026

New pooled data presented in the form of a scientific poster at the American Thoracic Society 2026 International Conference in Orlando suggests that sotatercept may significantly reduce morbidity and mortality risks in patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) — a particularly challenging population to treat. The analysis combined data from three phase

Efficacy and safety of sotatercept in patients with pulmonary arterial hypertension (PAH) associated with connective tissue disease (CTD), ATS international conference, May 18, 2026 Read Post »

“Transplantation Roadmap: Understanding the Role of Risk Assessment in Your Pulmonary Hypertension Plan”, June 2, 2026, 3 p.m. EDT

The Pulmonary Hypertension Association, PHA, is hosting a free webinar on transplant evaluation for people living with pulmonary hypertension and their caregivers. The session will cover how risk assessment works, how risk scores guide transplant referral and timing, and what questions to ask your care team — with perspectives on both adult and paediatric patients.

“Transplantation Roadmap: Understanding the Role of Risk Assessment in Your Pulmonary Hypertension Plan”, June 2, 2026, 3 p.m. EDT Read Post »

Flexible, Accessible, Effective: Patient Perceptions of the Pulmonary Hypertension and Home-Based (PHAHB) Physical Activity Intervention, Pulmonary Circulation, April 29, 2026

A 10-week fully remote, home-based exercise programme for people with pulmonary hypertension (pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) was found to be both acceptable and beneficial, according to a study conducted by a group of Irish researchers, based on qualitative interviews with 13 participants. The programme combined aerobic, resistance and respiratory

Flexible, Accessible, Effective: Patient Perceptions of the Pulmonary Hypertension and Home-Based (PHAHB) Physical Activity Intervention, Pulmonary Circulation, April 29, 2026 Read Post »

Lung Transplant Recipient Reaches Record High Altitude on Mount Aconcagua (6,961 m) during a scientific expedition, Transplant International, May 12, 2026

A 51-year-old lung transplant recipient — transplanted in 2002 for cystic fibrosis — successfully reached the summit of Mount Aconcagua in Argentina (6,961 m) in January 2026, without supplemental oxygen. This is the highest altitude ever recorded for a lung transplant recipient. The achievement was part of an international medical expedition organised by the Vienna

Lung Transplant Recipient Reaches Record High Altitude on Mount Aconcagua (6,961 m) during a scientific expedition, Transplant International, May 12, 2026 Read Post »

“Pulmonary hypertension and pulmonary arterial hypertension: a clarification is needed”, not a new article but still highly relevant today, ERS Editorial

This article is not new (it dates back to 2010) but we are publishing it because pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH) are often confused, whereas they are very different conditions with different diagnostic approaches and treatments. Mixing them up can lead to serious diagnostic and therapeutic errors. Key points: *Pulmonary hypertension is

“Pulmonary hypertension and pulmonary arterial hypertension: a clarification is needed”, not a new article but still highly relevant today, ERS Editorial Read Post »

Scientific review of current and emerging signalling pathways in pulmonary arterial hypertension, Current Opinions in Pulmonary Medicine, May 5, 2026

Researchers from Canada have published a review which summarizes recently established and emerging signalling pathways that may influence the next generation of targeted pulmonary arterial hypertension therapies. They note that the therapeutic landscape for this condition is moving towards mechanism-based approaches with the potential to alter the course of the disease. In particular, the transforming

Scientific review of current and emerging signalling pathways in pulmonary arterial hypertension, Current Opinions in Pulmonary Medicine, May 5, 2026 Read Post »

Remote exercise assessment in pulmonary hypertension, Current Opinions in Pulmonary Medicine, May 7, 2026

Assessment of exercise provides important prognostic information about pulmonary arterial hypertension patients. Researchers from the UK have recently published a review of current digital alternatives to traditional outcome measures. The 6-minute walk test (6MWT) is a key tool for monitoring pulmonary arterial hypertension, but since care is often centralized, patients may only do it once

Remote exercise assessment in pulmonary hypertension, Current Opinions in Pulmonary Medicine, May 7, 2026 Read Post »

Diagnostic and management dilemmas in pulmonary hypertension, European Respiratory Review 2026

Despite the comprehensive, evidence-based guidance offered by current international guidelines on the management of pulmonary hypertension, clinicians frequently encounter situations where the correct diagnosis or the most appropriate treatment remains uncertain. Methods A panel of pulmonary hypertension experts identified ten real-world diagnostic and management dilemmas during 2024–2025. For each, the available evidence was reviewed and

Diagnostic and management dilemmas in pulmonary hypertension, European Respiratory Review 2026 Read Post »

Economic burden of pulmonary arterial hypertension in Switzerland, Plos One, April 28, 2026

A cross-sectional Swiss study involving 124 pulmonary arterial hypertension patients across six centres estimated the annual cost at nearly €139,000 per patient, with direct healthcare costs accounting for 78.5% of this figure — driven predominantly by pharmacological treatment, which alone represented 65% of total costs. Indirect costs, including productivity losses and informal care, made up

Economic burden of pulmonary arterial hypertension in Switzerland, Plos One, April 28, 2026 Read Post »

Exploring the potential of “synthetic” control arms in clinical trials to reduce trial size, speed up recruitment, cut costs, improve early stage decision making, The Scientist, April 25, 2026

Qureight, a data science company, is using synthetic control arms — trial groups generated from existing real-world and historical datasets rather than traditional placebo groups. Their approach involves repeatedly drawing random patient samples from external datasets and matching them to trial participants on key baseline characteristics, generating hundreds of potential control arms. The method has

Exploring the potential of “synthetic” control arms in clinical trials to reduce trial size, speed up recruitment, cut costs, improve early stage decision making, The Scientist, April 25, 2026 Read Post »

Quality of life in patients with pulmonary arterial hypertension: A systematic review and meta-analysis, Health Quality of Life Outcomes, April 13, 2026

The importance of patient-reported outcome measures (PROMs) in assessing health-related QoL has been increasingly recognized, but their implementation remains inconsistent in clinical practice. A systematic review published on April 13, 2026 on Health Quality of Life Outcomes has synthesized the available evidence on the impact of pulmonary arterial hypertension on patients’ QoL measured by PROMs.

Quality of life in patients with pulmonary arterial hypertension: A systematic review and meta-analysis, Health Quality of Life Outcomes, April 13, 2026 Read Post »

Understanding how the right heart catheterisation works, the UK Pulmonary Hypertension Association (PHA UK)’s video of the month, April 2026

The right heart catheter – also known as cardiac catheterisation, and abbreviated as RHC –is considered the “gold standard’ test to diagnose pulmonary arterial hypertension, and at follow up to monitor progress of the condition and efficacy of treatments. In this video Dr Charlie Elliott, from the Sheffield Pulmonary Vascular Disease Unit, who has performed

Understanding how the right heart catheterisation works, the UK Pulmonary Hypertension Association (PHA UK)’s video of the month, April 2026 Read Post »

CardioMEMS-guided therapy shows promising results in pulmonary arterial hypertension: ARTISAN interim analysis presented at the American College of Cardiology Congress 2026, March 28–30

One of the most talked-about moments at this year’s American College of Cardiology Scientific Session was the presentation of the ARTISAN interim analysis by Dr. Raymond Benza — a study that was voted one of the Top 4 abstracts in Pulmonary Hypertension. ARTISAN (Afterload Reduction To Improve Right Ventricular Structure And FuNction), is a prospective, multicenter, open-label clinical

CardioMEMS-guided therapy shows promising results in pulmonary arterial hypertension: ARTISAN interim analysis presented at the American College of Cardiology Congress 2026, March 28–30 Read Post »

Self-Image and pulmonary hypertension: a study supported by the UK Pulmonary Hypertension Association explores how living with the condition can shape the way patients see themselves

With the support of the UK Pulmonary Hypertension Association (PHA UK), trainee psychologist Jacob Pendrey, at Cardiff University in Wales, conducted a study exploring how pulmonary hypertension affects self-image — and the findings are both striking and important. Pulmonary hypertension is known to alter daily life not only through physical limitations, but through profound social

Self-Image and pulmonary hypertension: a study supported by the UK Pulmonary Hypertension Association explores how living with the condition can shape the way patients see themselves Read Post »

Review of Pulmonary Arterial Hypertension (PAH) research in 2025: key trends and what they mean for patients, Pulmonary Therapy, April 8, 2026

A descriptive analysis of 54 pulmonary arterial hypertension-related clinical studies registered on international platforms in 2025 was recently published in Pulmonary Therapeutics. The review reveals an evolving and increasingly sophisticated research landscape. Nearly two thirds of the studies were interventional and one third observational, with most involving pharmacological interventions. Most trials involved pharmacological interventions and

Review of Pulmonary Arterial Hypertension (PAH) research in 2025: key trends and what they mean for patients, Pulmonary Therapy, April 8, 2026 Read Post »

Study suggests that pulmonary arterial hypertension extends beyond the cardiopulmonary system to affect brain structure and memory, Nature Scientific reports, April 3, 2026

Patients with pulmonary arterial hypertension often present neuropsychological symptoms, which suggest central nervous system involvement. A study conducted on rats with experimentally induced pulmonary arterial hypertension, recently published on Nature Scientific Reports showed reduced exploratory activity and cognitive impairment, alongside neuroinflammation in the cortex and hippocampus, disruption of the blood-brain barrier and elevated inflammatory markers.

Study suggests that pulmonary arterial hypertension extends beyond the cardiopulmonary system to affect brain structure and memory, Nature Scientific reports, April 3, 2026 Read Post »

New blood markers show promise for World Health Organisation (WHO) Group 2 pulmonary hypertension, Pulmonary Hypertension News, March 23, 2026

Pulmonary Hypertension News has recently reported on a small Chinese study exploring whether microRNAs — tiny molecules found in the blood that help regulate gene activity — could serve as non-invasive diagnostic markers for World Health Organisation (WHO) Group 2 pulmonary hypertension (pulmonary hypertension caused by left heart disease), potentially offering an alternative to the

New blood markers show promise for World Health Organisation (WHO) Group 2 pulmonary hypertension, Pulmonary Hypertension News, March 23, 2026 Read Post »

TRANSLATE »
Scroll to Top